Rubidium-82 chloride

From WikiMD's WELLNESSPEDIA

A radiopharmaceutical used in cardiac imaging

Rubidium-82 chloride is a radiopharmaceutical used in positron emission tomography (PET) imaging, particularly for assessing myocardial perfusion. It is a radioisotope of rubidium and is commonly used in the form of a generator system known as CardioGen-82.

Chemical properties[edit]

Rubidium-82 is a radioactive isotope of rubidium with a half-life of approximately 76 seconds. It decays by positron emission, which makes it suitable for PET imaging. The chloride form is used because it is soluble and can be easily administered intravenously.

Medical use[edit]

Rubidium-82 chloride is primarily used in cardiac imaging to evaluate coronary artery disease. It is injected into the bloodstream, where it mimics the behavior of potassium ions, allowing it to be taken up by myocardial tissue. This uptake is then imaged using PET to assess blood flow to the heart muscle.

CardioGen-82 generator[edit]

The CardioGen-82 generator is a device used to produce rubidium-82 chloride for clinical use. It contains a parent isotope, strontium-82, which decays to produce rubidium-82. The generator allows for the continuous production of rubidium-82, which is then eluted with a saline solution to produce the rubidium-82 chloride used in PET imaging.

Advantages and limitations[edit]

Rubidium-82 chloride offers several advantages in cardiac imaging, including rapid imaging times due to its short half-life and high-quality images due to the high energy of the emitted positrons. However, its short half-life also limits its use to facilities with an on-site generator, and the high cost of the generator system can be a barrier.

Safety and precautions[edit]

As with all radiopharmaceuticals, the use of rubidium-82 chloride requires careful handling to minimize radiation exposure to patients and healthcare workers. The short half-life of rubidium-82 helps reduce the overall radiation dose to the patient.

Related pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.